From PPS point of view, we will be closer to $20 once the results come out Q4 this year. The $1 billon market potential for this treatment will attract big pharma players driving the price probably higher. I see MDVN like move soon when it jumped from below 20 to 40+ in November last year and it's been parabolic since then....
Recall that the company has from FDA section 505 ROLLING NDA filing authority and they have ALREADY BEGUN that process. I think it is possible the NDA could be filed before the Jan options expire
News 
Market Data 
Discover 
